JAK-STAT and G-protein-coupled receptor signaling pathways are frequently altered in epitheliotropic intestinal T-cell lymphoma

Leukemia

Volumn 30, Issue 6, 2016, Pages 1311-1319

  Nairismagi M L ^a   Tan, J ^a,b   Lim, J Q ^a   Nagarajan, S ^a,b   Ng, C C Y ^a,b   Rajasegaran, V ^a,b   Huang, D ^a   Lim, W K ^a   Laurensia, Y ^a,b   Wijaya, G C ^a,b   Li, Z M ^a,b   Cutcutache, I ^b   Pang, W L ^a   Thangaraju, S ^a,b   Ha, J ^a   Khoo, L P ^a   Chin, S T ^a   Dey, S ^c   Poore, G ^d   Tan, L H C ^e   Koh, H K M ^f   Sabai, K ^f   Rao, H L ^g   Chuah, K L ^h   Ho, Y H ^h   Ng, S B ^h   Chuang, S S ^c,i,j   Zhang, F ^k,l   Liu, Y H ^m   Pongpruttipan, T ^m   Ko, Y H ⁿ   Cheah, P L ^o   Karim, N ^p   Chng, W J ^q   Tang, T ^a,j   Tao, M ^a   Tay, K ^a   Farid, M ^a   Quek, R ^a   Rozen, S G ^b   Tan, P ^b,c,r   Teh, B T ^a,b,s   Lim, S T ^a,b   Tan, S Y ^e,i,j,m,p,s   Ong, C K ^a   more..

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d Duke University   (United States)

^e SINGAPORE GENERAL HOSPITAL   (Singapore)

^f Singapore Health Services   (Singapore)

^g SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^h TAN TOCK SENG HOSPITAL   (Singapore)

ⁱ NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^j NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^k CHI MEI MEDICAL CENTER   (Taiwan)

^l TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^m GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

ⁿ MAHIDOL UNIVERSITY   (Thailand)

^o Sungkyunkwan University School of Medicine   (South Korea)

^p UNIVERSITY OF MALAYA   (Malaysia)

^q HOSPITAL RAJA PERMAISURI BAINUN   (Malaysia)

^r GENOME INSTITUTE OF SINGAPORE   (Singapore)

^s INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADDITIONAL SEX COMBLIKE TRANSCRIPTIONAL REGULATOR 3; CALCIUM BINDING PROTEIN; CARRIER PROTEIN; CONNECTIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; DYNEIN 9; DYNEIN ADENOSINE TRIPHOSPHATASE; G PROTEIN COUPLED RECEPTOR; HISTONE METHYLTRANSFERASE; INTERLEUKIN 2; INTERLEUKIN 9; INTRAFLAGELLAR TRANSPORT 140; JANUS KINASE 3; MULTIPLE EGF LIKE DOMAINS 6; ONCOSTATIN M; PROLINE RICH 16 PROTEIN; PROLINE RICH PROTEIN; REELIN; ROUNDABOUT 1; ROUNDABOUT RECEPTOR; SEMAPHORIN 3A; SET DOMAIN CONTAINING 2; STAT5B PROTEIN; UNCLASSIFIED DRUG; GNAI2 PROTEIN, HUMAN; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; JANUS KINASE; PROTEIN KINASE INHIBITOR; STAT PROTEIN; STAT5 PROTEIN; STAT5B PROTEIN, HUMAN;

AMPLICON; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHROMOSOME 17Q; CONTROLLED STUDY; EPITHELIOTROPIC INTESTINAL T CELL LYMPHOMA; EXOME; FEMALE; FRAMESHIFT MUTATION; GENE DUPLICATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE LOCUS; GENE MUTATION; GENE OVEREXPRESSION; GENE SEQUENCE; GENETIC SCREENING; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; MISSENSE MUTATION; MITOTIC RECOMBINATION; MOUSE; MUTATION RATE; NONHUMAN; NONSENSE MUTATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SOMATIC MUTATION; T CELL LYMPHOMA; UPREGULATION; ADULT; AGED; CELL CULTURE; CELL SURVIVAL; CLINICAL TRIAL; DRUG EFFECTS; ENTEROPATHY ASSOCIATED T CELL LYMPHOMA; GENETICS; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; MUTATION; PATHOLOGY; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CELL SURVIVAL; CELLS, CULTURED; ENTEROPATHY-ASSOCIATED T-CELL LYMPHOMA; FEMALE; GENE EXPRESSION PROFILING; GTP-BINDING PROTEIN ALPHA SUBUNIT, GI2; HUMANS; JANUS KINASE 3; JANUS KINASES; MALE; MIDDLE AGED; MUTATION; PROTEIN KINASE INHIBITORS; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; STAT5 TRANSCRIPTION FACTOR; YOUNG ADULT;

EID: 84959492009     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2016.13     Document Type: Article

References (53)

1. Isaacson PG, Chott A, Ott G, Stein H. Enteropathy-associated T-cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn IARC Press: Lyon, France, 2008, pp 289-291.
2. Delabie J, Holte H, Vose JM, Ullrich F, Jaffe ES, Savage KJ et al. Enteropathyassociated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project. Blood 2011; 118: 148-155.
3. Foukas PG, de Leval L. Recent advances in intestinal lymphomas. Histopathology 2015; 66: 112-136.
4. Shaw CK, Chen LL, Lee A, Lee TD. Distribution of HLA gene and haplotype frequencies in Taiwan: a comparative study among Min-nan, Hakka, Aborigines and Mainland Chinese. Tissue Antigens 1999; 53: 51-64.
5. Saito S, Ota S, Yamada E, Inoko H, Ota M. Allele frequencies and haplotypic associations defined by allelic DNA typing at HLA class I and class II loci in the Japanese population. Tissue Antigens 2000; 56: 522-529.
6. Liang CK, Chen KH, Hsu WM, Chen KH. Association of HLA type and Mooren's ulcer in Chinese in Taiwan. Br J Ophthalmol 2003; 87: 797-798.
7. Lee KW, Oh DH, Lee C, Yang SY. Allelic and haplotypic diversity of HLA-A,-B,-C,-DRB1, and-DQB1 genes in the Korean population. Tissue Antigens 2005; 65: 437-447.
8. Lan Q, Shen M, Garcia-Rossi D, Chanock S, Zheng T, Berndt SI et al. Genotype frequency and F ST analysis of polymorphisms in immunoregulatory genes in Chinese and Caucasian populations. Immunogenetics 2007; 59: 839-852.
9. Chim CS, Au WY, Shek TW, Ho J, Choy C, Ma SK et al. Primary CD56 positive lymphomas of the gastrointestinal tract. Cancer 2001; 91: 525-533.
10. Ko YH, Karnan S, Kim KM, Park CK, Kang ES, Kim YH et al. Enteropathy-associated T-cell lymphoma-a clinicopathologic and array comparative genomic hybridization study. Hum Pathol 2010; 41: 1231-1237.
11. Chan JK, Chan AC, Cheuk W, Wan SK, Lee WK, Lui YH et al. Type II enteropathyassociated T-cell lymphoma: a distinct aggressive lymphoma with frequent gammadelta T-cell receptor expression. Am J Surg Pathol 2011; 35: 1557-1569.
12. Sun J, Lu Z, Yang D, Chen J. Primary intestinal T-cell and NK-cell lymphomas: a clinicopathological and molecular study from China focused on type II enteropathy-associated T-cell lymphoma and primary intestinal NK-cell lymphoma. Mod Pathol 2011; 24: 983-992.
13. Tan SY, Chuang SS, Tang T, Tan L, Ko YH, Chuah KL et al. Type II EATL (epitheliotropic intestinal T-cell lymphoma): a neoplasm of intra-epithelial T-cells with predominant CD8alphaalpha phenotype. Leukemia 2013; 27: 1688-1696.
14. Chuang SS, Liao YL, Liu H, Lin SH, Hsieh PP, Huang WT et al. The phenotype of intraepithelial lymphocytes in Taiwanese enteropathy-associated T-cell lymphoma is distinct from that of the West. Histopathology 2008; 53: 234-236.
15. Tan SY, Ooi AS, Ang MK, Koh M, Wong JC, Dykema K et al. Nuclear expression of MATK is a novel marker of type II enteropathy-associated T-cell lymphoma. Leukemia 2011; 25: 555-557.
16. Okumura K, Ikebe M, Shimokama T, Takeshita M, Kinjo N, Sugimachi K et al. An unusual enteropathy-associated T-cell lymphoma with MYC translocation arising in a Japanese patient: a case report. World J Gastroenterol 2012; 18: 2434-2437.
17. Wilson AL, Swerdlow SH, Przybylski GK, Surti U, Choi JK, Campo E et al. Intestinal gammadelta T-cell lymphomas are most frequently of type II enteropathyassociated T-cell type. Hum Pathol 2013; 44: 1131-1145.
18. Kucuk C, Jiang B, Hu X, Zhang W, Chan JK, Xiao W et al. Activating mutations of STAT5B and STAT3 in lymphomas derived from gammadelta-T or NK cells. Nat Commun 2015; 6: 6025.
19. Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, Getz G et al. Integrative genomics viewer. Nat Biotechnol 2011; 29: 24-26.
20. Thorvaldsdottir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform 2013; 14: 178-192.
21. Cutcutache I, Suzuki Y, Tan IB, Ramgopal S, Zhang S, Ramnarayanan K et al. Exome-wide sequencing shows low mutation rates and identifies novel mutated genes in seminomas. Eur Urol 2015; 68: 77-83.
22. Pear WS, Miller JP, Xu L, Pui JC, Soffer B, Quackenbush RC et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 1998; 92: 3780-3792.
23. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 2002; 30: 207-210.
24. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 2011; 43: 491-498.
25. Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol 2013; 31: 213-219.
26. Saunders CT, Wong WS, Swamy S, Becq J, Murray LJ, Cheetham RK. Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. Bioinformatics 2012; 28: 1811-1817.
27. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G et al. Patterns of somatic mutation in human cancer genomes. Nature 2007; 446: 153-158.
28. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013; 499: 214-218.
29. Miller CA, White BS, Dees ND, Griffith M, Welch JS, Griffith OL et al. SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution. PLoS Comput Biol 2014; 10: e1003665.
30. Crescenzo R, Abate F, Lasorsa E, Tabbo F, Gaudiano M, Chiesa N et al. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell 2015; 27: 516-532.
31. Lyons J, Landis CA, Harsh G, Vallar L, Grunewald K, Feichtinger H et al. Two G protein oncogenes in human endocrine tumors. Science 1990; 249: 655-659.
32. Pace AM, Wong YH, Bourne HR. A mutant alpha subunit of Gi2 induces neoplastic transformation of Rat-1 cells. Proc Natl Acad Sci USA 1991; 88: 7031-7035.
33. Nishina H, Nimota K, Kukimoto I, Maehama T, Takahashi K, Hoshino S et al. Significance of Thr182 in the nucleotide-exchange and GTP-hydrolysis reactions of the alpha subunit of GTP-binding protein Gi2. J Biochem 1995; 118: 1083-1089.
34. O'Hayre M, Vazquez-Prado J, Kufareva I, Stawiski EW, Handel TM, Seshagiri S et al. The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer. Nat Rev Cancer 2013; 13: 412-424.
35. Leiserson MD, Wu HT, Vandin F, Raphael BJ. CoMEt: a statistical approach to identify combinations of mutually exclusive alterations in cancer. Genome Biol 2015; 16: 160.
36. Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011; 476: 298-303.
37. Pasqualucci L, Dominguez-Sola D, Chiarenza A, Fabbri G, Grunn A, Trifonov V et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 2011; 471: 189-195.
38. Green MR, Gentles AJ, Nair RV, Irish JM, Kihira S, Liu CL et al. Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood 2013; 121: 1604-1611.
39. Pastore A, Jurinovic V, Kridel R, Hoster E, Staiger AM, Szczepanowski M et al. Integration of gene mutations in risk prognostication for patients receiving firstline immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol 2015; 16: 1111-1122.
40. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al. A gain-offunction mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790.
41. Kawashima-Goto S, Imamura T, Seki M, Kato M, Yoshida K, Sugimoto A et al. Identification of a homozygous JAK3 V674A mutation caused by acquired uniparental disomy in a relapsed early T-cell precursor ALL patient. Int J Hematol 2015; 101: 411-416.
42. Mullighan CG, Zhang J, Kasper LH, Lerach S, Payne-Turner D, Phillips LA et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 2011; 471: 235-239.
43. Thorpe LM, Yuzugullu H, Zhao JJ. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer 2015; 15: 7-24.
44. Walker LJ, Kang YH, Smith MO, Tharmalingham H, Ramamurthy N, Fleming VM et al. Human MAIT and CD8alphaalpha cells develop from a pool of type-17 precommitted CD8+ T cells. Blood 2012; 119: 422-433.
45. Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics 2011; 27: 1739-1740.
46. Gu L, Vogiatzi P, Puhr M, Dagvadorj A, Lutz J, Ryder A et al. Stat5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo. Endocr Relat Cancer 2010; 17: 481-493.
47. Gupta SK, Gallego C, Johnson GL, Heasley LE. MAP kinase is constitutively activated in gip2 and src transformed rat 1a fibroblasts. J Biol Chem 1992; 267: 7987-7990.
48. van Biesen T, Luttrell LM, Hawes BE, Lefkowitz RJ. Mitogenic signaling via G protein-coupled receptors. Endocr Rev 1996; 17: 698-714.
49. Verma NK, Davies AM, Long A, Kelleher D, Volkov Y. STAT3 knockdown by siRNA induces apoptosis in human cutaneous T-cell lymphoma line Hut78 via downregulation of Bcl-xL. Cell Mol Biol Lett 2010; 15: 342-355.
50. Tiffon C, Adams J, van der Fits L, Wen S, Townsend P, Ganesan A et al. The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells. Br J Pharmacol 2011; 162: 1590-1602.
51. van der Fits L, Out-Luiting JJ, Tensen CP, Zoutman WH, Vermeer MH. Exploring the IL-21-STAT3 axis as therapeutic target for Sezary syndrome. J Invest Dermatol 2014; 134: 2639-2647.
52. McGirt LY, Jia P, Baerenwald DA, Duszynski RJ, Dahlman KB, Zic JA et al. Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides. Blood 2015; 126: 508-519.
53. Jeffrey KL, Camps M, Rommel C, Mackay CR. Targeting dual-specificity phosphatases: manipulating MAP kinase signalling and immune responses. Nat Rev Drug Discov 2007; 6: 391-403.